Back to Search
SAMUEL DENMEADE, M.D.
M.D.
Medical Oncology Physician
NPI: 1225073075Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D44576(MD)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Class of 1989
Research & Publications (20)
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer.
PMID 15662118·Cancer Biol Ther·2005
6-review
The role of prostate-specific antigen in the clinical evaluation of prostatic disease.
PMID 15009080·BJU Int·2004
6-review
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
PMID 12539223·Prostate·2003
7-preclinical
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
PMID 12837835·J Natl Cancer Inst·2003
7-preclinical
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
PMID 12746846·Prostate·2003
7-preclinical
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
PMID 11391681·Prostate·2001
4-observational
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
PMID 11433422·Prostate·2001
8-other
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
PMID 19275521·Anticancer Agents Med Chem·2009
6-review
Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.
PMID 19281249·Biochemistry·2009
7-preclinical
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
PMID 19417145·Mol Cancer Ther·2009
7-preclinical
Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.
PMID 19541487·Bioorg Med Chem·2009
8-other
Knockin of mutant PIK3CA activates multiple oncogenic pathways.
PMID 19196980·Proc Natl Acad Sci U S A·2009
7-preclinical
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.
PMID 19417147·Mol Cancer Ther·2009
7-preclinical
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.
PMID 18095711·Biochemistry·2008
8-other
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
PMID 18565882·J Clin Oncol·2008
3-trial
Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.
PMID 18635003·Chem Biol·2008
7-preclinical
Left posterior fascicular block due to high-dose interleukin-2.
PMID 18664608·Ann Pharmacother·2008
5-case
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA).
PMID 18698158·Cancer Biol Ther·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1225073075
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile